Level Bio AB (publ) (NGM:LEVBIO)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.2660
-0.0020 (-0.75%)
At close: Jul 18, 2025
-0.75%
Market Cap20.52M
Revenue (ttm)27.40M
Net Income (ttm)-6.25M
Shares Out68.40M
EPS (ttm)-0.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,000
Average Volume49,503
Openn/a
Previous Close0.2680
Day's Rangen/a
52-Week Range0.2000 - 0.4500
Beta0.48
RSI46.85
Earnings DateAug 15, 2025

About Level Bio AB

Level Bio AB (publ) manufactures and distributes cutting-edge solutions in the Nordic region and internationally. It also develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (publ) in May 2024. Level Bio AB (publ) was incorporated in 1998 and is headquartered in Stockholm, Sweden. [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 1998
Employees 11
Stock Exchange Nordic Growth Market
Ticker Symbol LEVBIO
Full Company Profile

Financial Performance

In 2024, Level Bio AB's revenue was 25.10 million, a decrease of -3.83% compared to the previous year's 26.10 million. Losses were -7.87 million, -16.92% less than in 2023.

Financial Statements

News

There is no news available yet.